Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Intranasal vs Oral Cannabidiol
NCT03471559Phase 1Terminated
- Sponsor
- Central Institute of Mental Health
- Start
- Dec 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cannabidiol in neuropsychiatric disorder, sponsored by Central Institute of Mental Health. Primary endpoint: Area under the curve from time zero to time t at 36 hours. Started Dec 2018; status: terminated.
02
Drugs
cannabidiol
03
Conditions
neuropsychiatric disorder
Beyond the preview
Go deeper on NCT03471559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03471559.